A comprehensive new hemostasis testing portfolio
Roche is moving towards a comprehensive new hemostasis testing portfolio with a number of industry firsts and innovative applications for early disease detection and monitoring. From easy-to-use, low-volume analyzers for self- and professional monitoring, to systems meeting the high efficiency requirements of the laboratory, Roche's products provide high quality results and offer outstanding productivity while reducing complexity.
Like Roche’s current instruments, the new generation of testing solutions is driven by a commitment to deliver high-quality, cost-effective solutions capable of addressing the current and future testing needs of a wide range of customers.
The cobas t 511 and cobas t 711 coagulation analyzers are the most recent addition to Roche’s hemostasis portfolio.